Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7390MR)

This product GTTS-WQ7390MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL), Chronic lymphocytic leukemia (CLL) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ7390MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13966MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN3470-3471-3479
GTTS-WQ13997MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ7418MR IVTScrip™ mRNA-Anti-EGFR, GA201(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA GA201
GTTS-WQ4004MR IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BGB-A317
GTTS-WQ13304MR IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PF-06523435
GTTS-WQ6055MR IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CNTO 136
GTTS-WQ7906MR IVTScrip™ mRNA-Anti-MAG, GSK-249320(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GSK-249320
GTTS-WQ1527MR IVTScrip™ mRNA-Anti-MSTN, ACE-031(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ACE-031
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW